Vera Therapeutics (VERA) to Release Quarterly Earnings on Thursday

Vera Therapeutics (NASDAQ:VERA - Get Free Report) is expected to release its Q1 2025 earnings data before the market opens on Thursday, May 8th. Analysts expect Vera Therapeutics to post earnings of ($0.75) per share for the quarter.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.83) by $0.11. On average, analysts expect Vera Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Vera Therapeutics Price Performance

Shares of Vera Therapeutics stock traded up $1.56 during trading hours on Friday, hitting $25.31. The company's stock had a trading volume of 1,629,779 shares, compared to its average volume of 752,305. The company has a market cap of $1.61 billion, a PE ratio of -9.70 and a beta of 1.28. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. The business has a 50 day moving average price of $24.82 and a two-hundred day moving average price of $35.33. Vera Therapeutics has a 12-month low of $18.53 and a 12-month high of $51.61.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Guggenheim upped their target price on shares of Vera Therapeutics from $59.00 to $61.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. Wolfe Research assumed coverage on Vera Therapeutics in a research report on Tuesday, February 4th. They set an "outperform" rating and a $49.00 price objective for the company. JPMorgan Chase & Co. decreased their target price on Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating on the stock in a research report on Tuesday, March 4th. Finally, The Goldman Sachs Group assumed coverage on Vera Therapeutics in a report on Tuesday, January 28th. They set a "buy" rating and a $58.00 price target for the company. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, Vera Therapeutics has a consensus rating of "Buy" and a consensus target price of $64.67.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.